VOTRIENT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VOTRIENT (VOTRIENT).
Pazopanib is a tyrosine kinase inhibitor that inhibits VEGFR-1, -2, -3, PDGFR-α/β, FGFR-1, -3, and c-Kit.
| Metabolism | Primarily metabolized by CYP3A4, with minor contributions from CYP1A2 and CYP2C8. |
| Excretion | Primarily hepatic metabolism via CYP3A4, with 57% excreted in feces (as metabolites) and 26% in urine (as metabolites). Less than 1% excreted unchanged in urine. |
| Half-life | Terminal half-life is 30-35 hours, supporting once-daily dosing. Steady state reached in approximately 2 weeks. |
| Protein binding | >99.5% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | Apparent Vd is approximately 6.3 L/kg (range 4.1-12.8 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is 20-30% (fasting state), which can be increased by food (especially high-fat meals). |
| Onset of Action | Oral: Therapeutic effect (tumor response) typically observed within 8-12 weeks, though onset varies by indication. |
| Duration of Action | Continuous daily dosing required for sustained effect. Duration of action is related to plasma concentration; drug levels decline slowly over 4-5 days after discontinuation. |
| Action Class | Tyrosine kinase inhibitors |
| Brand Substitutes | Pazocam 400mg Tablet, Pazoci 400 Tablet, Pazliz 400 Tablet, Pazocam 200mg Tablet, Pazolit 200mg Tablet, Pazoci 200 Tablet, Pazliz 200 Tablet, Pazolong 200mg Tablet |
800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal).
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | Child-Pugh Class A: 200 mg once daily; Child-Pugh Class B: 200 mg once daily; Child-Pugh Class C: not recommended. |
| Pediatric use | Safety and efficacy not established; no standard dosing recommendations. |
| Geriatric use | No specific dose adjustment based on age; monitor renal and hepatic function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VOTRIENT (VOTRIENT).
| Breastfeeding | No data on presence in human milk or effects on breastfed infant. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose. |
| Teratogenic Risk | Pregnancy Category D. Pazopanib is teratogenic in animal studies. First trimester exposure carries risk of major congenital malformations, including skeletal, cardiovascular, and neural tube defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and spontaneous abortion due to anti-angiogenic effects. Use is contraindicated in pregnancy. |
■ FDA Black Box Warning
Hepatotoxicity: Severe and fatal hepatotoxicity has been observed. Monitor liver function before and during treatment. Do not use in patients with severe hepatic impairment.
| Serious Effects |
["Severe hepatic impairment (Child-Pugh Class C)","Known hypersensitivity to pazopanib or any component of the formulation"]
| Precautions | ["Hepatotoxicity: Monitor LFTs; interrupt or discontinue if severe elevation occurs.","Cardiovascular effects: QT prolongation, hypertension, left ventricular dysfunction, and arterial thrombotic events.","Hemorrhage: Serious and fatal hemorrhage; use with caution in patients at high risk.","Gastrointestinal perforation or fistula: Discontinue if occurs.","Thyroid dysfunction: Monitor thyroid function prior to and during treatment.","Proteinuria: Monitor urine protein; discontinue for nephrotic syndrome.","Wound healing complications: Withhold for at least 7 days prior to elective surgery.","Posterior reversible encephalopathy syndrome (PRES): Discontinue if suspected.","Fetal harm: Can cause fetal harm; advise women of reproductive potential of potential risk."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure every 2 weeks, liver function tests (ALT, AST, bilirubin) every 4 weeks, thyroid function tests monthly, and urinalysis for proteinuria. Perform fetal ultrasound for growth and amniotic fluid volume every 4 weeks if exposed during pregnancy. |
| Fertility Effects | Pazopanib may impair female fertility by reducing ovarian function and inducing amenorrhea. In males, animal studies show reduced spermatogenesis and testicular degeneration. Reversibility unknown. |